Question 1

Why is this test performed?

Accepted Answer

To determine patient eligibility for BRAF and MEK inhibitors. To assist in the diagnosis of specific types of melanoma. To guide treatment decisions for colorectal and lung cancers.

Question 2

Target Groups

Accepted Answer

Patients diagnosed with metastatic melanoma. Individuals with advanced colorectal cancer. Patients with non-small cell lung cancer (NSCLC).

Question 3

Interpreting Results

Accepted Answer

Positive Result: Indicates the presence of the mutation and potential benefit from targeted therapy. Negative Result: Indicates the absence of the mutation, suggesting other treatment options.

Precision Testing for Targeted Therapy - BRAF V600 Mutation Molecular Testing